A Study of HIV Levels During Pregnancy and After Childbirth
A Prospective Observational Study of Virologic and Immunologic Changes in HIV-Infected Women During the Postpartum Period
The purpose of this study is to find out if HIV-infected pregnant women taking anti-HIV drugs have an increased amount of HIV in their blood (viral load) after having the baby.
The purpose of A5153s, a substudy of A5150, is to characterize two anti-HIV drugs (nelfinavir [NFV] and lopinavir/ritonavir [LPV/r]) in HIV-infected women during pregnancy and after childbirth.
Sometimes pregnant women have an increase in their HIV viral load after their baby is born. This study will try to find out how often this happens. It will also examine possible reasons why the increase in viral load occurs.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Limited data suggest that HIV-infected pregnant women develop postpartum viral rebound. However, viral load changes in the postpartum period have not been adequately characterized. Changes in adherence to antiretroviral therapy, pregnancy-related changes in pharmacokinetics of antiretroviral medications, and decline in immune competence are mechanisms by which postpartum viral load rebound may occur. This study is designed to characterize the incidence and magnitude of postpartum viral rebound during the initial 24 weeks postpartum and to explore the mechanisms and consequences of viral rebound.
Eligible patients are evaluated at gestational weeks 34 and 36, at delivery, and at regular visits for 96 weeks postpartum. Most evaluations include a medical history, physical exam, laboratory tests, and adherence and quality-of-life questionnaires. Viral load and CD4/CD8 cell counts are measured frequently.
Patients are expected to receive at least 8 weeks of stable HAART before delivery, and to continue HAART throughout the remainder of the study. The choice of HAART is left to the primary provider. No antiretroviral drugs are provided by this study.
Patients participating in the A5153s substudy receive either NFV or LPV/r as part of their HAART. Pharmacokinetic blood sampling takes place at 36 weeks gestation, 6 weeks postpartum, and 24 weeks postpartum. Patients record the administration times and doses of their NFV or LPV/r for 48 hours prior to each substudy visit, and hold their regularly scheduled doses of antiretroviral medications on substudy days. Patients arrive at the clinic fasting (no food or drink for the previous 8 hours) and are given a standardized breakfast prior to supervised administration of their NFV or LPV/r dose. An intravenous catheter is placed in an arm vein for blood collection at pre-dose and 1, 2, 4, and 6 hours post-dose.
Tipo de estudio
Inscripción
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- Univ of Alabama at Birmingham
-
-
California
-
Los Angeles, California, Estados Unidos, 90095-1793
- UCLA School of Medicine
-
Los Angeles, California, Estados Unidos, 90033
- Los Angeles County Medical Center/USC
-
San Diego, California, Estados Unidos, 92103
- UCSD Mother, Child & Adolescent HIV Program
-
San Francisco, California, Estados Unidos, 94110
- San Francisco General Hosp
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32209
- Univ of Florida- Health Science Ctr
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30308
- Emory Univ
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 98616-2396
- University of Hawaii
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Rush Presbyterian - Saint Luke's Med Ctr
-
Chicago, Illinois, Estados Unidos, 60611-3015
- Northwestern University
-
Chicago, Illinois, Estados Unidos, 60612
- Cook County Hosp Core Ctr
-
Chicago, Illinois, Estados Unidos, 60614
- Chicago Childrens Memorial Hospital (Pediatric)
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Indiana Univ Hosp
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Childrens Hospital of Michigan
-
Detroit, Michigan, Estados Unidos, 48201-1427
- Hutzel Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455-0392
- Hennepin County Med Clinic
-
-
New Jersey
-
Newark, New Jersey, Estados Unidos, 07103
- Univ of Med & Dentistry of NJ/Univ Hosp
-
-
New York
-
Bronx, New York, Estados Unidos, 10461
- Jacobi Med Ctr
-
New York, New York, Estados Unidos, 10032-3784
- Columbia University
-
New York,, New York, Estados Unidos, 10016-6481
- NYU/Bellevue
-
Stony Brook, New York, Estados Unidos, 11794-8111
- State Univ of New York at Stony Brook
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- Univ of North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Duke Univ Med Ctr
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- Case Western Reserve Univ
-
Cleveland, Ohio, Estados Unidos, 44109-1998
- MetroHealth Med Ctr
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213-2582
- University of Pittsburgh
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02906
- Miriam Hosp / Brown Univ
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38105-2794
- The Regional Med Ctr, Memphis
-
Nashville, Tennessee, Estados Unidos, 37203
- Comprehensive Care Clinic
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75235-9173
- University of Texas, Southwestern Medical Center
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98104
- Univ of Washington (Seattle)
-
-
-
-
-
San Juan, Puerto Rico
- San Juan City Hosp
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria
Patients may be eligible for this study if they:
- Are age 13 or older.
- Are between 22 and 30 weeks pregnant.
- Have had their pregnancy confirmed by ultrasound at 14 weeks gestation or later.
- Are infected with HIV.
- Are planning to receive at least 8 weeks of highly active antiretroviral therapy (HAART) by the time they have their baby.
- Are available for follow-up for the duration of the study.
Exclusion Criteria
Patients may not be eligible for this study if they:
- Intend to terminate their pregnancy.
- Intend to breast-feed their baby.
- Are carrying a baby with major abnormalities, including spina bifida, anencephaly, hydrops, or ascites.
- Have taken certain medications.
- Are enrolled in other studies that require large blood draws.
- Will be taking anti-HIV drugs only to prevent mother-to-child transmission of HIV, and not to treat the maternal infection itself.
- Actively abuse drugs or alcohol in a way that would interfere with participation in the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Colaboradores e Investigadores
Investigadores
- Silla de estudio: Beverly Sha
- Silla de estudio: Alice Stek
Publicaciones y enlaces útiles
Publicaciones Generales
- Melvin AJ, Burchett SK, Watts DH, Hitti J, Hughes JP, McLellan CL, King PD, Johnson EJ, Williams BL, Frenkel LM, Coombs RW. Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 1;14(3):232-6. doi: 10.1097/00042560-199703010-00006.
- Rich KC, Siegel JN, Jennings C, Rydman RJ, Landay AL. CD4+ lymphocytes in perinatal human immunodeficiency virus (HIV) infection: evidence for pregnancy-induced immune depression in uninfected and HIV-infected women. J Infect Dis. 1995 Nov;172(5):1221-7. doi: 10.1093/infdis/172.5.1221.
- Cao Y, Krogstad P, Korber BT, Koup RA, Muldoon M, Macken C, Song JL, Jin Z, Zhao JQ, Clapp S, Chen IS, Ho DD, Ammann AJ. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med. 1997 May;3(5):549-52. doi: 10.1038/nm0597-549.
- Burns DN, Landesman S, Minkoff H, Wright DJ, Waters D, Mitchell RM, Rubinstein A, Willoughby A, Goedert JJ. The influence of pregnancy on human immunodeficiency virus type 1 infection: antepartum and postpartum changes in human immunodeficiency virus type 1 viral load. Am J Obstet Gynecol. 1998 Feb;178(2):355-9. doi: 10.1016/s0002-9378(98)80025-2.
- Sha BE, Tierney C, Cohn SE, Sun X, Coombs RW, Frenkel LM, Kalams SA, Aweeka FT, Bastow B, Bardeguez A, Kmack A, Stek A; Aids Clinical Trials Group ACTG A5150 Team. Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150. HIV Clin Trials. 2011 Jan-Feb;12(1):9-23. doi: 10.1310/hct1201-9.
Fechas de registro del estudio
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Enfermedades del sistema inmunológico
- Infecciones por VIH
Otros números de identificación del estudio
- ACTG A5150
- ACTG A5153s
- AACTG A5150
- AACTG A5153s
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Infecciones por VIH
-
Icahn School of Medicine at Mount SinaiIRRASReclutamientoHemorragia Intraventricular (HIV)Estados Unidos
-
Yale UniversityTerminadoPrecocidad | Recién nacidos de muy bajo peso al nacer | Hemorragia Intraventricular (HIV) | Sangrado en el cerebroEstados Unidos
-
China Medical University HospitalDesconocidoDisplasia broncopulmonar | Bebés extremadamente prematuros | TLP grave que las terapias convencionales han fallado | Sin anomalías congénitas graves | no Hiv Severa Ni FPV QuísticaTaiwán